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Abstract
Background For patients with an identified germline E-cadherin-1 (CDH1) mutation, prophylactic gastrectomy is the treatment
of choice to eliminate the high risk of developing diffuse gastric cancer. Laparoscopic total gastrectomy with jejunal pouch
reconstruction is a novel approach that may be especially suitable in these patients.
Methods Patients with a germline CDH1 mutation who underwent prophylactic laparoscopic total gastrectomy with jejunal
pouch were included in our prospective database.
Results A total of 11 patients with a median age of 40 (22–61)years were included. The average operative time was 4:26±0:49 h
and the average blood loss was 219±155 ml. Median length of hospital stay was 10 (7–27)days. In two patients, an
esophagojejunal anastomotic leakage occurred (grade 4). The leakages were seen in patient numbers 2 and 3, which may be a
result of a learning curve. The latter eight patients did not develop anastomotic leakage. Pulmonary complications occurred in one
patient with atelectasis and in one patient with pneumonia (grade 2). The 60-day mortality rate was 0 %. Multiple foci of
intramucosal diffuse gastric signet ring cell carcinoma were found in the resection specimen of 9/11 (82 %) patients. All 11/11
(100 %) resections were microscopically radical.
Conclusions Prophylactic laparoscopic total gastrectomy with jejunal pouch reconstruction in patients with a CDH1 germline
mutation is feasible and safe. In 82 % of patients, foci of intramucosal diffuse gastric signet ring cell carcinoma in the resection
specimen were found.
Keywords Gastrectomy . Laparoscopy . Prophylactic .
E-cadherin . Cancer
Introduction
The estimated number of newly diagnosed gastric cancer pa-
tients is 989,600 worldwide, accounting for 738,000 cancer-
related deaths.1 This number counts for 10 % of all cancer-
related deaths, ranking gastric cancer the second highest cause
of cancer death.1
Hereditary diffuse gastric cancer represents 1–3 % of all gas-
tric cancers.2 In approximately 30 % of families with hereditary
diffuse gastric cancer, germline mutations are found in the E-
cadherin-1 (CDH1) tumor suppressor gene.3–6 The CDH1 gene
codes for the E-cadherin protein, and loss of function of the
CDH1 gene leads to diffuse gastric cancer. Patients who carry
CDH1 germline mutations have a lifetime risk of >70 % of
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developing diffuse gastric cancer with a 5-year survival of less
than 20 %.7,8 Female carriers also have an increased risk to
develop lobular breast cancer.9–11 Surgery eliminates the high
risk of developing diffuse gastric cancer in patients with germline
CDH1 mutations and therefore is the treatment of choice. Most
reports on prophylactic total gastrectomy in literature describe a
conventional open surgical approach.12
In gastric cancer, laparoscopic total gastrectomy showed
diminished blood loss, fewer postoperative complications,
and shorter postoperative hospital stay.13 This technique
may therefore be especially suitable for prophylactic surgery.
In this article, we describe our initial experience with prophy-
lactic laparoscopic total gastrectomy with jejunal pouch in a
case series of patients carrying a CDH1 germline mutation.
Materials and Methods
Patients
Patients (n=11) with identified germline CDH1 mutations
who were referred to the University Medical Centre Utrecht
for prophylactic total gastrectomy between April 2006 and
May 2015 were included in this study. All patients were pre-
sented and discussed in amultidisciplinary teammeeting com-
prising oncologic surgeons, medical oncologists, gastroenter-
ologist, clinical geneticist, radiologists, and nutritionist prior
to treatment. Patient information was recorded into a prospec-
tively maintained database and included demographics, pre-
operative clinical work-up, surgical results and postoperative
complications, pathological results, length of hospital stay,
and follow-up. No routine upper gastrointestinal contrast stud-
ies were performed to detect anastomotic leakage, instead ra-
diological diagnosis was performed when clinical signs of
leakage were present. Complications were scored with the
modified Clavien-Dindo classification.14
Surgery
All patients underwent prophylactic laparoscopic total gas-
trectomy by surgeons experienced in laparoscopic techniques
(RvH and JPR). All patients received an epidural catheter to
provide adequate postoperative analgesia. Prophylactic antibi-
otics were administered pre-operatively. After an open intro-
duction of a first trocar in the left hypogastrium, pneumoperi-
toneum was created and the abdominal cavity was inspected,
and two 5-mm trocars were introduced subcostally on both
sides and two 12-mm trocars in the right hypogastrium and
the right flank under direct sight (Fig. 1). The lesser sac was
opened and transected closely to the liver. The left crus of the
diaphragm was exposed. Hereafter, the greater gastric curva-
ture was dissected using a harmonic scalpel (Ethicon
Endosurgery, Southington, CT, USA) followed by dissection
and ligation of the left gastric artery and vein. The right
gastroepiploic artery and vein were dissected and ligated at the
level of the duodenum. The duodenum was divided postpyloric
with an Endo-GIA stapler (Covidien, Norwalk, CT, USA). The
esophagus wasmobilized, and a supporting suture was placed on
both sides followed by transection of the distal esophagus with
an Endo-GIA stapler (Fig. 2). An Orvil stapler (Covidien, Nor-
walk, CT, USA) anchor was introduced through the oral cavity
into the esophagus. In the stapled distal esophagus, an opening
was created for the Orvil anchor, which was fixed by a
laparoscopically placed purse-string suture around the anchor.
A horizontal incision in the left upper abdomen, with spar-
ing of the rectus muscle, was created through the left 12-mm
port, and an Endopath DextrusTM (Ethicon Endosurgery,
Southington, CT, USA) access port was inserted. The resec-
tion specimen was removed through this port and was sent in
for frozen section evaluation (Fig. 3). The first bowel loopwas
divided with an Endo-GIA stapler, and the Roux-en-Y recon-
struction was completed with an isoperistaltic side-to-side
jejunal-jejunal anastomosis manually created with a PDS 3.0
continuous suture. The distal jejunum was used to create a
Fig. 1 Trocar arrangement during prophylactic laparoscopic total
gastrectomy. The camera was inserted through the 10-mm para-
umbilical trocar port and two 5-mm trocars were used as laparoscopic
working ports. The liver retractor was inserted through the 12-mm right
para-rectal trocar port. The harmonic scalpel was inserted through the 12-
mm para-umbilical port. The horizontal line represents the incision that is
used to take out the stomach
Fig. 2 Placement of a supporting suture on both sides of the esophagus
followed by transection of the esophagus by means of an Endo-GIA
stapler
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BJ^-shaped pouch (Fig. 4), using a 100-mm linear stapler
(Covidien, Norwalk, CT, USA). An antecolic 10-cm esopha-
geal (pouch)-jejunal (EJ) anastomosis was created with the
Orvil circular stapler (Fig. 5). The proximal and distal
esophageal-jejunal donuts were pathologically examined.
The blind jejunal loop was stapled. Distal to this anastomosis,
a feeding jejunostomy was inserted.
Pathological Analysis
The resection specimen was evaluated using a standard proto-
col, providing information on resection margins and presence
of tumor cells. The specimen was completely accessioned; after
resection of the proximal and distal margin, the remaining mu-
cosa was cleaved from the underlying deep muscle and fixed
overnight according to the so-called Swiss roll technique.15
This method consists of isolating a thin strip of gastric mucosa
(approximately 4 mm thick) from the underlying layers and
rolling it up in a spiral starting from the distal (duodenal)
margin. This enables complete microscopic investigation of
whole gastric mucosa and is particularly suitable when no mac-
roscopic lesions can be recognized.15
Results
A total of 11 patients (eight females, three males) who carried
the CDH1 gene mutation were included and underwent
Fig. 3 Removal of the gastric resection specimen through the Endopath
DextrusTM access port
Fig. 4 Creation of a BJ^-shaped jejunal pouch, using a 100-mm linear
stapler
Fig. 5 Creation of an esophagojejunal anastomosis with jejunal pouch
with the use of the Orvil circular stapler
Table 1 Baseline characteristics
Laparoscopic prophylactic
gastrectomy
N=11
Agea 40 (22–61)
Gender (male/female) 3:8
BMIa 27.8 (19.7–35.2)
Comorbidities
Diabetes mellitus 0
COPD 0
Cardiovascular 1
ASA score
1 6
2 4
3 1
Smoking 6
Alcohol 5
a Data presented as median (min–max)
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prophylactic laparoscopic total gastrectomy. The median age
at the time of surgery of was 40 (22–61)years (Table 1). All
patients had an ASA score of 1, 2, or 3. The average operative
time was 4:26±0:49 h (Table 2). The average blood loss was
219±155 ml. No blood transfusions were required. One pro-
cedure was converted to an open procedure due to an incom-
plete anastomosis identified during the procedure, which ne-
cessitated additional stitches. The median length of postoper-
ative hospital stay was 10 (7–23)days.
In two patients, anastomotic leakage occurred which were
treated either by intraoperative anastomotic repair or endo-
scopic placement of a stent (grades 3–4). Both leakages were
detected after surgery. No intraoperative leak test was routine-
ly performed. The first patient was stented due to fistula for-
mation at the level of the anastomosis, and the second patient
underwent a re-operation during which an anastomotic dehis-
cence was seen. This defect was oversewn after which the
patient recovered uneventfully. The leakages were seen in
patient numbers 2 and 3, which may be a result of a learning
curve. The latter eight patients did not develop anastomotic
leakage. Minor complications were observed in two patients.
One patient suffered from atelectasis and a wound infection,
which were treated conservatively (grade 1). One of these
patients had a pneumonia, which was treated with intravenous
antibiotics (grade 2). The remaining four patients had no early
postoperative complications (<30 days postoperatively).
After microscopy of the complete resection specimen, mul-
tiple foci of intramucosal diffuse gastric signet ring cell carci-
noma or focal intestinal metaplasia were found in the resection
specimen of 9/11 (82 %) patients (Fig. 6). The largest focus
was 8 mm in diameter. A median of 10 (1–25) lymph nodes
were dissected during laparoscopy, none of which were tumor
positive.
Discussion
In this article, we report our initial experience with prophylactic
laparoscopic total gastrectomy with jejunal pouch in patients
with a CDH1 germline mutation. In 9/11 (82 %) patients, mul-
tiple foci of intramucosal diffuse gastric signet ring cell carci-
noma were found in the resection specimens. The laparoscopic
technique was shown to be feasible and safe with an average
blood loss of 219±155ml and median length of hospital stay of
10 days. Postoperative complications occurred in 6/11 (55 %)
patients, and the 60-day hospital mortality rate was 0 %.
Our prophylactic gastrectomy resection specimens were
microscopically analyzed using the BSwiss roll^ technique.
In this fashion, the complete gastric mucosa could be scruti-
nized by expert pathologists.15 In our cohort, multiple foci of
intramucosal gastric cancer were found in the resection spec-
imens in 82 % of patients. This is in concordance with other
series, where the presence of one or more foci of signet ring
cell carcinoma was reported in up to 92 % of all prophylactic
gastrectomy pathologic resection specimens.3,16,17 The high
percentage of intramucosal gastric cancer in both our series
and the series from literature emphasizes the need for prophy-
lactic gastrectomy for patients with germline CDH1
mutations.
In a meta-analysis, we demonstrated that laparoscopic total
gastrectomy is associated with reduced intraoperative blood
loss, lower risk at postoperative complications, and shorter
hospital stay compared to open total gastrectomy in patients
with gastric cancer.13 These benefits are especially relevant for
patients with a CDH1 germline mutation. Our initial experi-
ence with the prophylactic laparoscopic total gastrectomy is
promising. We expect that the outcomes of prophylactic lapa-
roscopic total gastrectomy will approximate the results for
laparoscopic total gastrectomy for gastric cancer in larger se-
ries of patients with a CDH1 germline mutation.
The median length of hospital stay in our cohort was
10 days. This is higher than reported in a case report of pa-
tients that had prophylactic laparoscopic total gastrectomy
(median length of hospital stay was 5 days).18 This might be
due to the fact that this was our initial experience, and these
results may have been part of our learning curve. According to
literature, the learning curve for total gastrectomy is 23
procedures.19 The current study included 11 patients, so an
actual learning curve was not analyzed. Also, in our series,
all patients were placed on a nil-by-mouth routine with enteral
tube feeding by a needle-catheter jejunostomy the first 7 days
postoperatively. Results may be further improved by implying
a fast recovery protocol with early start on clear liquid diets
and early mobilization.20
A D1 lymph node dissection was performed in this cohort
of patients according to the international guidelines.21 We
found that the laparoscopic procedure yielded a median of
10 lymph nodes. All dissected lymph nodes were negative
Table 2 Intraoperative and postoperative outcomes
Laparoscopic prophylactic
gastrectomy
N=11
Duration of surgery (h)a 4:26±0:49
Blood loss (ml)a 219±155
Conversion 1
Complicated course 5
Postoperative hospital stay (day)b 10 (7–23)
Intensive care stay (day)b 0 (0–2)
Resected lymph nodes (n)b 10 (1–25)
R0 resection 11
Mortality
30-day mortality 0 %
60-day mortality 0 %
aAverage±standard deviation
bMedian (min–max)
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for metastases. This is in accordance with literature describing
the removal of 10–12 lymph nodes, none of which contained
metastases.12 Until now, after a median follow-up time of 28
(9–110)months, no recurrent disease or distant metastases
were observed in our cohort, suggesting that a limited lymph
node dissection is the appropriate procedure for these patients.
Compared to open total gastrectomy for gastric cancer, lap-
aroscopic total gastrectomy showed less blood loss, fewer
postoperative complications, and shorter hospital admission
time as well in this series as in literature.13 Most probably, this
is the result of less surgical trauma. The severity of surgical
trauma can be assessed by measuring the serum levels of the
acute-phase response cytokine IL-6. A recent systematic re-
view indicated that an open procedure is associated with a
higher inflammatory response, as is measured by IL-6 levels
compared to a laparoscopic procedure.22 Unlike laparoscopic
distal gastrectomy, laparoscopic total gastrectomy is still not
widely accepted as first choice of treatment. This is probably a
reflection of laparoscopic total gastrectomy being a technical-
ly more demanding procedure than laparoscopic distal gas-
trectomy with a long learning curve.23
Conclusion
In conclusion, we showed that prophylactic laparoscopic total
gastrectomy with jejunal pouch for patients with germline
CDH1 mutation is feasible and safe. Laparoscopic total gas-
trectomy is associated with less intraoperative blood loss,
fewer postoperative complications, and shorter hospital ad-
mission time in comparison to open total gastrectomy. These
benefits may be especially relevant to patients with germline
CDH1 mutation. We therefore recommend experienced sur-
geons to consider prophylactic laparoscopic total gastrectomy
as first choice for these patients.
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